Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.investoren.team/attachments/jj-27-08-png.2097/
"In order to prevent honest investors from being mislead, it should be noted that NRx announced in May 2021 that it provided the same Clinical Study Report to RLF as it provided to the US FDA. Patients must always come first." -----------wrote JJ ago few minutes
and a reminder - RLF has had ADVITA from Germany in its portfolio for several months. This treasure has long owned protected patent rights over inhalation of aviptadil......why should RLF pay 4 million?
In Europe we see this situation very relaxed!
How STUPID are you----and as RAM settles with its employer Wainwright the latest funding just days ago for NRXP?
READ or REMEMBER (if you can..) & shutup
https://ge.usembassy.gov/lugar-center-supports-georgian-ncdc-on-covid-19-response/
July 27, 2021
NRx Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia
With more than one thousand new cases of the delta variant diagnosed in Georgia every day, NRx Pharmaceuticals is pleased the Prime Minister and Minister of Health of Georgia have granted Emergency Use Authorization of ZYESAMI™ for those suffering the worst of COVID-19.
Further details about this regulatory decision and the rollout of ZYESAMI™ in Georgia will be forthcoming.
Read this.....https://www.sec.gov/Archives/edgar/data/1719406/000119312521118931/d56937dex1031.htm and you will see NO PROBLEM--all is on the wax
READ completely...........best DD
insert-text-here
AND to confirm (screamer)
insert-text-here
This shit can believe (even writing) who wants....
The fact is that a few weeks ago in an investor conference the RLF CFO JW announced partnerships in India /Mexico/ Russia to
Is correct--has been taken over by Relief with all protective rights. But now IMPORTANT to question India...
In the JJs contribution of the APRIL stands in the indicated (and best DD whre ever) DD......
insert-text-here
.....If even one of these indications can be added to VIP’s clinical indications for use, market cap will increase exponentially above where it is already headed. At risk of pumping, its reasonable to conclude that RLF/NeuroRx may be become the next Moderna, rising like a phoenix from the ashes to become the newest big pharma. GLTA.
CATALYSTS:
1 - Planned "near term uplisting" of RLFTF to NASDAQ (confirmed by CFO in the Biotech Investor Showcase)
2- EAP data on 300+ compassionate use patients
3 -Initiation of the inhalation trial – reported on 2/3/20 with top line results pending 1H2021
4 - I-SPY trial results for inhaled VIP vs remdesavir
5- Inclusion in NIH/TESICO/Active3b Trial (pg 18 of the NeuroRx investor presentation)
6 - BRPA merger completion
7 - Possible stockpiling agreements/OWS/Barda – described as pending phase 3 results with expected purchase of 100k treatments quarterly and 30k treatments up front
8 - Partnership announcements with McKesson, Cardinal and AmerisourceBergen (Reported by CFO orally in the biotech investor presentation)
9 - Mexico, India, Russia feedback/partnerships (reported by CFO in the biotech investor presentation)
https://preventivemedicine.usc.edu/events/beyond-vaccines-the-role-of-repurposed-therapeutics-in-preventing-covid-19-deaths/
Begining soon!! with Jane from the FDA! Dont miss..
The context of this FDA survey is not our drug. This has already been confirmed as safe AND effective......
The FDA needs the broad information for those far-reaching healing applications, which we already know (only in part)............including inhalations!!!
Such tactical intent of BP etc. would have been used in the context against our drug and use much earlier - there the train has already sailed!
Are you deliberately forgetting the inhaler?
For me, JJ failed completely as a doctor ...
I have to correct it now ....... this company with the inhalation studies and already advanced successes / bought by Relief (because Javitt (with son - do you remember?) Had already started with the inhaler topic on his own, contrary to the IV Aviptadil agreements is the German company AdVita ---- not ACER!
I think this action was right to finally close this shit GAP between the US / German market ..........
Full Acton from tomorrow .....
What nonsense ---- take a look over the horizon, what about BARDA / NIH?
Apparently some have not yet grasped it, Zyesami However ... Heals !! (Don't forget your inhaler) considerably more diseases.
Ram is a native Indian with best connections
We are facing the THIRD wave of infections in Europe (not only in the EU) .... we have to protect our hospitals ---- and that is certainly not only possible with vaccines (where we now know that problems arise with a mutation ... further mutations will follow ...!)
In this complex context we know - our medi has a lot of effect - never forget
Sorry - also in German, as there is a lot of reading along here
Wir stehen in Europa (nicht nur in EU) vor der DRITTEN Infektionswelle....wir müssen unsere Krankenhäuser schützen----und das geht sicher nicht nur mit Vaccines (wo wir jetzt wissen, das bei einer Mutation Probleme auftauchen...weiter Mutationen folgen werden...!)
In diesen komplexen Zusammenhang wissen wir-- unser Medi hat viel Wirkung --- niemals vergessen
I think the FDA sees it the same way I do ..... I remember, this was also communicated by JJ and focused on SURVIVAL in the ongoing study!
The market (a lot of investors), however, have inappropriately burned in the comparative figures of the dead from the first open study.
.... and JJ went public with this "story" yesterday ----------- but that's a much different story!
I try to explain the situation (point of contention) simply ...
RT and especially JJ had started their PR after viewing the first open study with a completely wrong heading (which, however, is still true according to today's knowledge) !! Remember: "RLF / Aviptatil however --- SAVES human lives!
It should have been right then AND now ...... SAVES human lives according to the current SOC (Knowledge at that time) .....
According to today's SOC, at least after 28 days, the same number of people will survive without Zyesamy (let's wait for the rest of the data, which I wish each and every one of them to survive! I don't need to write ALL the other current and certainly later advantages of our Medi again ... .
As far as I know (please correct who is wrong), the requirement of the FDA (to others as well) was ... to determine significant differences in survival from severe courses to other treatments .....
And this is exactly where our medi is still unmatched!
..... and what does this report confirm about Eli Lilly's bamlanivimab and Regeneron's cocktail!
At best with caution for emergencies among many other difficulties! READ report --- not positive.
Today's report on the inhaler study has discreetly confirmed a much more important message for us! ------ "ZYESAMI ™ is a synthetic form of human Vasoactive Intestinal Peptide (VIP). Emerging data indicate that the drug protects the alveolar type II cells upon which the lung depends on the production of surfactant and which are the primary target of the SARS-CoV-2 Coronavirus.
TOK ... TOK ..... TOK The matching domain, aviptacare.net, was already on January 12th. secured.
Great......= new calculation
"NeuroRx has arranged with the Nephron pharmaceutical group to initiate scaleup of aviptadil acetate 100µg/ml in saline. Pending review of the clinical data, NeuroRx is prepared to order the first 10,000 patient courses of treatment in the first quarter of 2021. At 1,500µg aviptadil per treatment kit, NeuroRx would have sufficient drug product in hand to supply 10,000 kits. NeuroRx has contracted with Bachem to supply 1 KG of Aviptadil during the first quarter of 2021, and glass syringes would be supplied by Nephron to support this order. NeuroRx has sufficient API on order to meet two years of supply at 100,000 patient doses per quarter. "
Thank you - I forgot the copy
Now let's sit back and relax ... earmuffs and good thoughts. For doubters about the good future (data) MY conviction = 1) ... we would have no chance of further studies & inhaler 2) ... we would not have these larger investors (until a few days ago) 3) ... the one with RAM yesterday Coordinated investor letter is a mirror image of a professional who knows how to fly under the radar towards the climax (and not to annoy his big investors ..) 4) ... I think some of you didn't really understand my last sentences about these Indian patent infringements - very simply put (... join him) = some of the BP who had to lead litigation with India ... (have price obligations / arguments towards the real market!) and now live very well with (or in addition to generics ) continue ----- Don't forget - RAM = Indian !!!
If, contrary to my expectation, there should be difficulties with the data = only a question of time when at least our current SP can move significantly upwards again - however, we have so far secured not a few people the SURVIVAL ....
if you cant buy him join him
Be relaxed .... 1) RLFT has always communicated the further search for partners (who are able to serve larger markets) 2) Zuventus Health Care (India ... The group has subsidiaries in Dubai, Brazil, South Africa, Singapore and Nigeria and branch offices in Russia, Morocco and Shanghai.)
Works closely with the US FDA agency to be able to act quickly worldwide!
For this size - and the necessary speed (BigDeal), RLTF & NRX would be completely overwhelmed!
I think great news and another piece of good data.
JB .. do you remember my hint? ---- (RLF International)
Relief Therapeutics buys German Advita
01/21/2021
from tt
Relief Therapeutics plans to take over the life science company for EUR 25 million and invest up to EUR 20 million.
Relief Therapeutics Holding AG in Geneva plans to buy Advita Lifescience GmbH in Denzlingen near Freiburg for EUR 25 million, and the company has announced a letter of intent. They also agreed on success-related milestone payments of up to EUR 20 million. The goal is to develop a COVID-19 therapeutic agent.
Relief will acquire all shares in Advita. In return, Advita Relief will receive ordinary shares worth EUR 25 million as well as the milestone payments. The transaction is expected to close in the second quarter of 2021.
Relief is a biopharmaceutical company whose lead drug candidate RLF-100 (Aviptadil) is in advanced clinical development for the treatment of patients with severe COVID-19 disease. Among other things, Advita develops products to improve the treatment and diagnosis of rare lung diseases. In addition to the Advita assets, Relief claims that it will receive further pending patent rights covering the specifications for inhaled RLF-100 formulations and the possible use of Aviptadil as inhalative therapy for acute respiratory distress syndrome (ARDS) and checkpoint inhibitor cover induced pneumonitis.
"Advita's intellectual property with respect to inhaled formulations of Aviptadil and the company's expertise with respect to this active ingredient will be used in the development of the inhaled formulation of RLF-100 for the treatment of COVID-19-related ARDS and other potential indications in the area of Lung diseases such as pulmonary sarcoid and chronic berylliasis will be invaluable, "said Jack Weinstein, chief financial officer of Relief.
© transkript.de
This company was founded by the University Clinic Freiburg ...... with all the advantages of studying ...
Website - in German...
https://advita-lifescience.com/mission/
Shame - from Jan 20 (I only checked now)
From the YF - Report from Jan 21
This was culled from a research report of the aviptadil clinical trial at Methodist Hospital, Houston:
"KEY POINTS
Question: Does intravenous aviptadil (Vasoactive Intestinal Peptide) improve survival and recovery from respiratory failure in patients with Critical COVID-19 and major comorbidity.
Findings: In this administratively-controlled clinical trial, intravenous aviptadil, administered as 3 successive 12 hour infusions of 50/100/150 pmol/kg/hr resulted in a 9-fold advantage in both survival and recovery from respiratory failure compared to standard of care with all approved therapy for COVID-19 among patients treated in the same ICU by the same clinical care team. Notably, 4 of 5 aviptadil-treated patients on Extracorporeal Membrane Oxygenation were successfully decannulated and survived, compared to 3 of 13 control patients. Although 20% of patients exhibited hypotension and/or diarrhea, no drug-related serious adverse events were seen.
Meaning: Intravenous aviptadil demonstrated a dramatic level of efficacy that is consistent with FDA guidance for administratively-controlled clinical trials and may be warranted for use in highly-comorbid patients with Critical COVID-19 and respiratory failure."
From the YF..
today on swiss television there was a report on a swiss start-up which had nothing to sell as a pharmaceutical product at the start of the year. in 2013 the Pictet bank in Geneva had invested. Her boss is the only one who dared to say to Trump in January "we will make a vaccine for this year" the continuation we all know: MODERNA I also know a small Swiss company that has the potential to cure patients but not only covid ... respiratory diseases
Relief thérapeutics....
Il faut seulement être patient ( You just have to be patient..)
My summary: 1) What is fact .... 2) What must come ... 3) Opportunities / risks
1) the big picture is certainly not a fraud - a drug similar to the effect of penicillin - property rights - 2 companies who want the same with 1 drug (RLFT will NEVER dilute its property rights in negotiations - worst case in negotiations with NRX / GEM by many billions sell to BP - however CashCow is for all of us in a huge / growing market!
2) Changes to the current structure (share volume - companies - stock exchanges ..) must be changed for this market / shareholder structure .. - full approval of the drug (starting with EUA shortly!
3) In the short term, the ideas of investors may be different - medium / long-term see under point 2
All just my opinion ...
Basically, an RS is completely neutral = PRESENTATION: 1/10
Now 100 K - after 10000K ---- Now investment capital pSh $ 0.001 = market price now $ 0.32 .------- Immediately after RS base capital and market price 10x higher! HOWEVER !!!! If there is NO real good news at (before) RS, investors will certainly react negatively --- that is the risk for everyone !!
an uplisting on Nasdq / Nyse would certainly have significant advantages in the future - but not immediately!
@ Tiger Money
... NRX / RLFT = one US company xxxxxx (advantages Barda / approvals / Nasdaq ..) and don't forget !! - A few weeks ago the currently insignificant company "RLFT International" was activated !! ...
(in this context I remind J-Belfort "..Built in safety switch !! = before GM - GEM was 50% >> now << 50% ......
@ VF- please turn on your brain, I wouldn't necessarily announce my logistics partner now = risk of embezzlement / theft / robberies ..